Methylphenidate of retard forms in children and adolescents with ADHD - An overview;Methylphenidat-retard-präparate bei kindern und jugendlichen mit ADHS - Eine übersicht

Klinische Padiatrie

Volumn 220, Issue 2, 2008, Pages 93-100

  Pelz, R ^a   Banaschewski, T ^a   Becker, K ^a  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

Author keywords

ADHD; Methylphenidate; Pharmacotherapy; Retarded forms of methyl phenidate side effects

Indexed keywords

AMPHETAMINE; AMPHETAMINE DERIVATIVE; DEXAMPHETAMINE; DEXEDRINE SPANSULE; DEXIDRENE SPANSULE; DEXMETHYLPHENIDATE; EQUASYM RETARD; MEDIKINET; MEDIKINET RETARD; METHYLPHENI TAD; METHYLPHENIDATE; PIPERIDINE DERIVATIVE; PSYCHOSTIMULANT AGENT; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; CLINICAL PRACTICE; CLINICAL STUDY; DRUG EFFICACY; DRUG SYNTHESIS; HUMAN; MAXIMUM PLASMA CONCENTRATION; PHARMACODYNAMICS; PSYCHOEDUCATION; REVIEW; SUSTAINED DRUG RELEASE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 42049103626     PISSN: 03008630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-985864     Document Type: Review

References (46)

1. American Academy of Pediatrics. Clinical Practice Guideline: Diagnosis and Evaluation of the Child With Attention-Deficit/Hyperactivity Disorder. Pediatrics 2000; 105: 1158-1170
2. American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders 4th ed. Washington, DC 1994
3. Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, Danckaerts M, Dopfner M, Faraone SV, Rothenberger A, Sergeant J, Steinhausen HC, Sonuga-Barke EJ, Taylor E. Long-acting medications for the hyperkinetic disorders: A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 2006; 15: 476-495
4. Barkley RA, Fischer M, Smallish L, Fletcher K. Young adult follow-up of hyperactive children: Antisocial activities and drug use. Journal of Child Psychology and Psychiatry 2004; 45: 195-211
5. Baumgaertel A, Wolraich M, Dietrich M. Comparison of diagnostic criteria for attention deficit disorder in a German elementary school sample. J. Am. Acad. Child Adolesc Psychiatry 1995; 34: 629-638
6. Deutsche Gesellschaft für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie et al. (Hrsg). Döpfner M, Lehmkuhl G. Hyperkinetische Störungen (F90). Leitlinien zu Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes- und Jugendalter 3.überarbeitete und erweiterte Auflage. Deutscher Ärzte-Verlag 2007
7. Döpfner M, Lehmkuhl G. Evidenzbasierte Therapie von Kindern und Jugendlichen mit ADHS. Prax Kinderpsychol Kinderpsychiatr 2002; 51: 419-440
8. Döpfner M, Gerber WD, Banaschewski T, Breuer D, Freisleder FJ, Gerbervon Muller G, Gunter M, Hassler F, Ose C, Rothenberger A, Schmeck K, Sinzig J, Stadler C, Uebel H, Lehmkuhl G. Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting. Eur Child Adolesc Psychiatry 2004; 13 (Suppl 1): 193-101
9. Dillon A. Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents. National Institute of Clinical Excellence, London 2006
10. Faraone SV, Wilens T. Does stimulant treatment lead to substance use disorders? Journal of Clinical Psychiatry 2003; 64 (Suppl 11): 9-13
11. Gonzalez MA, Pentikis HS, Anderl N, Benedict MF, Cory HH De, Dirksen SJ, Hatch SJ. Methylphenidate bioavailability from two extended-release formulations. Int J Clin Pharmacol Ther 2002; 40: 175-184
12. Holtkamp K, Peters-Wallraf B, Wüller S, Pfäffle R, Herpertz-Dahlmann B. Case Report: Methylphenidate-related growth impairment. J Child Adolesc Psychopharm 2002; 12: 55-61
13. Jadad AR, Booker L, Gould M, Kakuma R, Boyle M, Cunningham CE, Kim M, Schachar R. The treatment of attention-deficit hyperactivity disorder: An annotated bibliography and critical appraisal of published systematic reviews and metaanalyses. Can J Psychiatr 1999; 44: 1025-1035
14. Janssen-Cilag GmbH. Fachinformation Concerta® 18 mg/36 mg/54 mg Retardtabletten. 41457 Neuss. www.janssen-cilag.de
15. Jerome L. Can methylphenidate facilitate sleep in children with attention deficit hyperactivity disorder? J Child Adolesc Psychopharm 2001; 11: 109
16. Kent JD, Blader JC, Koplewicz HS, Abikoff H, Foley CA. Effects of late-afternoon methylphenidate administration on behavior and sleep in attention-deficit hyperactivity disorder. Pediatrics 1995; 96: 320-325
17. Kimko HC, Cross JT, Abernethy DR. Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet 1999; 37: 457-470
18. King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, Golder S, Taylor E, Drummond M, Riemsma R Methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children (commercial in confidence information removed) 2004; Centre for Reviews and Dissemination (CRD): http://www.nice.org.uk/pdf/ADHD_assessment_report.pdf
19. Lisska MC, Rivkees SA. Daily methylphenidate use slows growth of children: a community based study. J Pediatr Endocrinol Metab 2003; 16: 711-718
20. Lopez F, Silva R, Pestreich L, Muniz R. Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day. Paediatr Drugs 2003; 5: 545-555
21. Mannuzza S, Klein R, Bessler A, Malloy P, LaPadula M. Adult outcome of hyperactive boys grown up. Arch Gen Psychiatry 1998; 155: 493-498
22. Marchetti A, Magar R, Lau H, Murphy EL, Jensen PS, Conners CK, Findling R, Wineburg E, Carotenuto I, Einarson TR, Iskedjian M. Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis. Clin Ther 2001; 23: 1904-1921 39
23. Markowitz JS, Straughn AB, Patrick KS, Vane CL De, Pestreich L, Lee J, Wang Y, Muniz R. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. Clin Pharmacokinet 2003; 42: 393-401
24. MEDICE Arzneimittel Pütter GmbH & Co.KG. FACHINFORMATION Medikinet retard 10 mg/20 mg/30 mg/40 mg. Kuhloweg 37, 58638 Iserlohn http://www.medice.de.
25. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention deficit/hyperactivity disorder. Archives of General Psychiatry 1999a; 56: 1073-1086
26. MTA Cooperative Group. Moderators and mediators of treatment response for children with attentiondeficit/hyperactivity disorder. Archives of General Psychiatry 1999b; 56: 1088-1096
27. Novartis Pharmaceuticals Corp. Ritalin LA (methylphenidate HCL) product monograph. East Hanover (NJ): Novartis Pharmaceuticals Corp 2002
28. Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fielbelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD. Once a day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001; 107: E105
29. Pelham WE, Karen E, Greenslade KE, Vodde-Hamilton M, Murphy DA, Greenstein JJ, Gnagy EM, Guthrie KJ, Hoover MD, Dahl RE. Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: A comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and Pemoline. Pediatrics 1990; 86: 226-236
30. Pliszka SR, Greenhill LL, Crismon ML, Sedillo A, Carlson C, Conners CK, MacCracken JT, Swanson JM, Hughes CW, Llana ME, Lopez M, Toprac MG. The texas children's medication algorithm project: report of the texas consensus conference panel on medication treatment of childhood attention-deficit/ hyperactivity disorder. Attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc Psychiatry 2000; 39: 908-927
31. Remschmidt H, Schmidt M, Poustka F. Multiaxial classification of child and adolescent psychiatric disorders [In German: Multiaxiales Klassifikationsschema für psychische Störungen des Kindes- und Jugendalters nach ICD-10 und DSM.IV.] 4. überarbeitete und erweiterte Auflage, Bern 2001
32. Rupprecht T, Schellmoser S, Wagner M, Wenzel D, Topf HG. Aufmerksamkeitsdefizit-Hyperaktivitäts-Syndrom (ADHS). Monatsschr Kinderheilkd 2005; 153: 463-468
33. Sevecke K, Dittmann R, Lehmkuhl G, Döpfner M. Atomoxetinbehandlung von Kindern und Jugendlichen mit ADHS. Monatsschr Kinderheilkd 2006; 154: 894-902
34. Sinzig JK, Gontard A von. Absences as differential diagnosis in children with attention-deficit disorder. Klin Padiatr. 2005; 217: 230-233
35. SIGN (Scottish Intercoligiate Guidelines Networt). Attention deficit and hyperkinetic disorders in children and young people: a national clinical guideline Vol. 52. Edinburgh 2001
36. SIGN (Scottish Intercoligiate Guidelines Networt). A guidelines developer's handbook. SIGN, Edinburgh 2004
37. Sonuga-Barke EJ, Swanson JM, Coghill D, Cory HH De, Hatch SJ. Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data. BMC Psychiatry 2004; 4: 28
38. Spencer T, Biederman J, Wilens T, Harding M, O'Donnell D, Griffin S. Pharmacotherapy of Attention-Deficit Hyperactivity Disorder across the life cycle. J. Am. Acad. Child Adolesc Psychiatry 1996; 35: 409-432
39. Swanson J, Greenhill L, Pelham W, Wilens T, Wolraich M, Abikoff H, Atkins M, August G, Biederman J, Bukstein O, Conners CK, Efron L, Fiebelkorn K, Fried J, Hoffman M, Lambrecht L, Lerner M, Leventhal B, MacBurnett K, Morse E, Palumbo D, Pfiffner L, Stein M, Wigal SB, Winans E. Initiating Concerta TM (Oros_methylphenidate HCl) in children with attention-deficit hyperactivity disorder. J Clin Res 2000; 3: 59-76
40. Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics 2004; 113: e206-e216
41. Taylor E, Döpfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Rothenberger A, Sonuga-Barke E, Steinhausen HC, Zuddas A. European clinical guidelines for hyperkinetic disorder - first upgrade. Eur Child Adolesc Psychiatry 2004; 13 (Suppl 1): 17-30
42. Taylor E, Sergeant J, Doepfner M, Gunning B, Overmeyer S, Möbius H-J, Eisert H-G. Clinical guidelines for hyperkinetic disorder. Eur Child Adolesc Psychiatry 1998; 7: 184-200
43. UCB GmbH 2006. Fachinformation. Equasym® Retard. Hü ttenstraße 205, 50170 Kerpen.
44. Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003; 111: 179-185
45. Wilens T, Pelham W, Stein M, Conners KC, Abikoff H, Atkins M, August G, Greenhill L, MacBurnett K, Palumbo D, Swanson J, Wolraich M. ADHD treatment with once-daily OROS® methylphenidate: interim 12-month results from a long-tetm open-label study. J. Am. Acad. Child Adolesc Psychiatry 2003; 42: 424-433
46. Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, Atkins M, MacBurnett K, Bukstein O, August G. Randomized, controlled trial of oros methylphenidate once a day in children with attentiondeficit/ hyperactivity disorder. Pediatrics 2001; 108: 883-892